Home » Stocks » SLRX

Salarius Pharmaceuticals, Inc. (SLRX)

Stock Price: $1.20 USD -0.01 (-0.83%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
Pre-market: $1.19 -0.01 (-0.83%) Jun 16, 8:44 AM
Market Cap 53.73M
Revenue (ttm) 5.37M
Net Income (ttm) -7.52M
Shares Out 30.55M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $1.20
Previous Close $1.21
Change ($) -0.01
Change (%) -0.83%
Day's Open 1.21
Day's Range 1.18 - 1.23
Day's Volume 1,471,590
52-Week Range 0.63 - 3.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an ope...

21 hours ago - Benzinga

Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML) Clinical trial to targ...

1 day ago - GlobeNewsWire

Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET

5 days ago - GlobeNewsWire

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) presented data at the American Society of Clinical Oncology Virtual Annual Meeting for seclidemstat, a reversible inhibitor of the lysine-specific histone dem...

1 week ago - Benzinga

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial

1 week ago - GlobeNewsWire

Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials

3 weeks ago - GlobeNewsWire

Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: IDEX, MNMD
4 weeks ago - PennyStocks

Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 72.73% year over year to ($0.06), which mis...

1 month ago - Benzinga

Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat

1 month ago - GlobeNewsWire

Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET

1 month ago - GlobeNewsWire

HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...

1 month ago - GlobeNewsWire

HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...

1 month ago - GlobeNewsWire

Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 77.27% over the past year to ($0.10)...

2 months ago - Benzinga

Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET

2 months ago - GlobeNewsWire

Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET

3 months ago - GlobeNewsWire

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...

3 months ago - GlobeNewsWire

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...

3 months ago - GlobeNewsWire

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...

Other stocks mentioned: PRAH, PSTX, SNSS
3 months ago - Benzinga

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

3 months ago - GlobeNewsWire

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established

3 months ago - GlobeNewsWire

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors,...

4 months ago - GlobeNewsWire

HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

4 months ago - GlobeNewsWire

HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...

5 months ago - GlobeNewsWire

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

5 months ago - GlobeNewsWire

HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors,...

5 months ago - GlobeNewsWire

HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

6 months ago - GlobeNewsWire

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

6 months ago - GlobeNewsWire

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

6 months ago - GlobeNewsWire

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET

7 months ago - GlobeNewsWire

Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET

7 months ago - GlobeNewsWire

HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Execu...

8 months ago - GlobeNewsWire

Presentations Will Highlight Corporate and Clinical Progress Presentations Will Highlight Corporate and Clinical Progress

9 months ago - GlobeNewsWire

Webcast presentation scheduled for Tuesday, September 1, 2020 Webcast presentation scheduled for Tuesday, September 1, 2020

9 months ago - GlobeNewsWire

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas

10 months ago - GlobeNewsWire

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET

10 months ago - GlobeNewsWire

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032

10 months ago - GlobeNewsWire

HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced th...

10 months ago - GlobeNewsWire

HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced ...

10 months ago - GlobeNewsWire

Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas Pre-Clinical Data and Early Clinical Observations...

10 months ago - GlobeNewsWire

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

Other stocks mentioned: BIIB, CHRS, GEN, LXRX
10 months ago - Benzinga

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020

1 year ago - GlobeNewsWire

Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director Board of Directors Seeks the Election of Jonathan...

1 year ago - GlobeNewsWire

European Patent Office Satisfied Patent Application Meets All Requirements

1 year ago - GlobeNewsWire

HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced th...

1 year ago - GlobeNewsWire

HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an...

1 year ago - GlobeNewsWire

Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study

1 year ago - GlobeNewsWire

About SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, ... [Read more...]

Industry
Biotechnology
CEO
David Arthur
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
SLRX
Full Company Profile

Financial Performance

In 2020, SLRX's revenue was $5.23 million, an increase of 51.03% compared to the previous year's $3.47 million. Losses were -$7.35 million, 6.00% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SLRX stock is "Strong Buy." The 12-month stock price forecast is 4.10, which is an increase of 241.67% from the latest price.

Price Target
$4.10
(241.67% upside)
Analyst Consensus: Strong Buy